-
1
-
-
84920272288
-
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes
-
PID: 24786708
-
Molitch ME, Adler AI, Flyvbjerg A et al (2015) Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int 87:20–30
-
(2015)
Kidney Int
, vol.87
, pp. 20-30
-
-
Molitch, M.E.1
Adler, A.I.2
Flyvbjerg, A.3
-
2
-
-
79953235256
-
Relation of albuminuria to angiographically determined coronary arterial narrowing in patients with and without type 2 diabetes mellitus and stable or suspected coronary artery disease
-
PID: 21324429
-
Rein P, Vonbank A, Saely CH et al (2011) Relation of albuminuria to angiographically determined coronary arterial narrowing in patients with and without type 2 diabetes mellitus and stable or suspected coronary artery disease. Am J Cardiol 107:1144–1148
-
(2011)
Am J Cardiol
, vol.107
, pp. 1144-1148
-
-
Rein, P.1
Vonbank, A.2
Saely, C.H.3
-
3
-
-
84922251376
-
Renal outcomes in patients with type 1 diabetes and macroalbuminuria
-
PID: 24925722
-
de Boer IH, Afkarian M, Rue TC et al (2014) Renal outcomes in patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 25:2342–2350
-
(2014)
J Am Soc Nephrol
, vol.25
, pp. 2342-2350
-
-
de Boer, I.H.1
Afkarian, M.2
Rue, T.C.3
-
4
-
-
59849097777
-
Insights into the regulation of renal hemodynamic function in diabetic mellitus
-
COI: 1:CAS:528:DC%2BD1cXhtlKqsbzI, PID: 18991597
-
Cherney DZ, Scholey JW, Miller JA (2008) Insights into the regulation of renal hemodynamic function in diabetic mellitus. Curr Diabetes Rev 4:280–290
-
(2008)
Curr Diabetes Rev
, vol.4
, pp. 280-290
-
-
Cherney, D.Z.1
Scholey, J.W.2
Miller, J.A.3
-
5
-
-
84863796440
-
Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers
-
PID: 22437412
-
Lambers Heerspink HJ, Holtkamp FA et al (2012) Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 82:330–337
-
(2012)
Kidney Int
, vol.82
, pp. 330-337
-
-
Lambers Heerspink, H.J.1
Holtkamp, F.A.2
-
6
-
-
33845271259
-
Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up
-
PID: 17130264
-
Navarro-Diaz M, Serra A, Romero R et al (2006) Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J Am Soc Nephrol 17(Suppl 3):S213–S217
-
(2006)
J Am Soc Nephrol
, vol.17
, pp. S213-S217
-
-
Navarro-Diaz, M.1
Serra, A.2
Romero, R.3
-
7
-
-
84885954870
-
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
-
COI: 1:CAS:528:DC%2BC2cXosFSks7k%3D, PID: 24622369
-
Roden M, Weng J, Eilbracht J et al (2013) Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1:208–219
-
(2013)
Lancet Diabetes Endocrinol
, vol.1
, pp. 208-219
-
-
Roden, M.1
Weng, J.2
Eilbracht, J.3
-
8
-
-
84885952950
-
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial
-
PID: 23963895
-
Häring HU, Merker L, Seewaldt-Becker E et al (2013) Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 36:3396–3404
-
(2013)
Diabetes Care
, vol.36
, pp. 3396-3404
-
-
Häring, H.U.1
Merker, L.2
Seewaldt-Becker, E.3
-
9
-
-
84901455931
-
Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial
-
PID: 24722494
-
Häring HU, Merker L, Seewaldt-Becker E et al (2014) Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37:1650–1659
-
(2014)
Diabetes Care
, vol.37
, pp. 1650-1659
-
-
Häring, H.U.1
Merker, L.2
Seewaldt-Becker, E.3
-
10
-
-
84892477577
-
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
-
COI: 1:CAS:528:DC%2BC2cXptFWgsQ%3D%3D, PID: 23906415
-
Kovacs CS, Seshiah V, Swallow R et al (2014) Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16:147–158
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 147-158
-
-
Kovacs, C.S.1
Seshiah, V.2
Swallow, R.3
-
11
-
-
84893214045
-
The renal hemodynamic effect of SGLT2 inhibition in patients with type 1 diabetes
-
COI: 1:CAS:528:DC%2BC2cXitFSqtLg%3D, PID: 24334175
-
Cherney DZI, Perkins BA, Soleymanlou N et al (2014) The renal hemodynamic effect of SGLT2 inhibition in patients with type 1 diabetes. Circulation 129:587–597
-
(2014)
Circulation
, vol.129
, pp. 587-597
-
-
Cherney, D.Z.I.1
Perkins, B.A.2
Soleymanlou, N.3
-
12
-
-
84933523949
-
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
-
PID: 25280671
-
Škrtić M, Yang GK, Perkins BA et al (2014) Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 57:2599–2602
-
(2014)
Diabetologia
, vol.57
, pp. 2599-2602
-
-
Škrtić, M.1
Yang, G.K.2
Perkins, B.A.3
-
13
-
-
84880850027
-
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
-
COI: 1:CAS:528:DC%2BC3sXhtFygsr%2FE, PID: 23668478
-
Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J (2013) Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15:853–862
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 853-862
-
-
Lambers Heerspink, H.J.1
de Zeeuw, D.2
Wie, L.3
Leslie, B.4
List, J.5
-
14
-
-
84908514103
-
Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
-
COI: 1:CAS:528:DC%2BC2cXhvVKmtb%2FP, PID: 25360497
-
Cherney DZ, Perkins BA, Soleymanlou N et al (2014) Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int 86:1057–1058
-
(2014)
Kidney Int
, vol.86
, pp. 1057-1058
-
-
Cherney, D.Z.1
Perkins, B.A.2
Soleymanlou, N.3
-
15
-
-
84899961819
-
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
-
COI: 1:CAS:528:DC%2BC2cXnslaqsbw%3D, PID: 24795251
-
Barnett AH, Mithal A, Manassie J et al (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2:369–384
-
(2014)
Lancet Diabetes Endocrinol
, vol.2
, pp. 369-384
-
-
Barnett, A.H.1
Mithal, A.2
Manassie, J.3
-
16
-
-
78149359262
-
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
-
PID: 21055801
-
de Zeeuw D, Agarwal R, Amdahl M et al (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376:1543–1551
-
(2010)
Lancet
, vol.376
, pp. 1543-1551
-
-
de Zeeuw, D.1
Agarwal, R.2
Amdahl, M.3
-
17
-
-
84890476805
-
Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction
-
COI: 1:CAS:528:DC%2BC3sXhsl2ht7vN, PID: 24026560
-
Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M (2013) Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 36:3460–3468
-
(2013)
Diabetes Care
, vol.36
, pp. 3460-3468
-
-
Groop, P.H.1
Cooper, M.E.2
Perkovic, V.3
Emser, A.4
Woerle, H.J.5
von Eynatten, M.6
-
18
-
-
84892588641
-
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
-
COI: 1:CAS:528:DC%2BC2cXitleit7Y%3D, PID: 24226524
-
Vallon V, Gerasimova M, Rose MA et al (2014) SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306:F194–F204
-
(2014)
Am J Physiol Renal Physiol
, vol.306
, pp. F194-F204
-
-
Vallon, V.1
Gerasimova, M.2
Rose, M.A.3
-
19
-
-
84902536157
-
Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats
-
COI: 1:CAS:528:DC%2BC2cXps1Ohsbc%3D, PID: 24533859
-
Tahara A, Kurosaki E, Yokono M et al (2014) Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol 66:975–987
-
(2014)
J Pharm Pharmacol
, vol.66
, pp. 975-987
-
-
Tahara, A.1
Kurosaki, E.2
Yokono, M.3
-
20
-
-
56149087069
-
Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats
-
Malatiali S, Francis I, Barac-Nieto M (2008) Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp Diabetes Res 2008:305–403
-
(2008)
Exp Diabetes Res
, vol.2008
, pp. 305-403
-
-
Malatiali, S.1
Francis, I.2
Barac-Nieto, M.3
-
21
-
-
0035122471
-
Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095
-
COI: 1:CAS:528:DC%2BD3MXht1Snsrw%3D, PID: 11159708
-
Arakawa K, Ishihara T, Oku A et al (2001) Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 132:578–586
-
(2001)
Br J Pharmacol
, vol.132
, pp. 578-586
-
-
Arakawa, K.1
Ishihara, T.2
Oku, A.3
-
22
-
-
84905238756
-
The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension
-
COI: 1:CAS:528:DC%2BC2cXhsFanu77O, PID: 24944269
-
Gembardt F, Bartaun C, Jarzebska N et al (2014) The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol 307:F317–F325
-
(2014)
Am J Physiol Renal Physiol
, vol.307
, pp. F317-F325
-
-
Gembardt, F.1
Bartaun, C.2
Jarzebska, N.3
-
23
-
-
84897394040
-
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
-
COI: 1:CAS:528:DC%2BC3sXhsFequr3L, PID: 24067431
-
Kohan DE, Fioretto P, Tang W, List JF (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85:962–971
-
(2014)
Kidney Int
, vol.85
, pp. 962-971
-
-
Kohan, D.E.1
Fioretto, P.2
Tang, W.3
List, J.F.4
-
24
-
-
84876311251
-
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
-
COI: 1:CAS:528:DC%2BC3sXlvVenu7c%3D, PID: 23464594
-
Yale JF, Bakris G, Cariou B et al (2013) Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15:463–473
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 463-473
-
-
Yale, J.F.1
Bakris, G.2
Cariou, B.3
-
25
-
-
85010952053
-
Dapagliflozin reduces albuminuria in hypertensive diabetic patients using renin-angiotensin blockers
-
Heerspink HJL, Johnsson E, Gause-Nilsson I, Cain VA, Sjostrom CD (2016) Dapagliflozin reduces albuminuria in hypertensive diabetic patients using renin-angiotensin blockers. Diabetes Obes Metab 18:590–597
-
(2016)
Diabetes Obes Metab
, vol.18
, pp. 590-597
-
-
Heerspink, H.J.L.1
Johnsson, E.2
Gause-Nilsson, I.3
Cain, V.A.4
Sjostrom, C.D.5
-
26
-
-
84255185190
-
Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
-
COI: 1:CAS:528:DC%2BC38XitVemsL4%3D, PID: 21940401
-
Thomson SC, Rieg T, Miracle C et al (2012) Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 302:R75–R83
-
(2012)
Am J Physiol Regul Integr Comp Physiol
, vol.302
, pp. R75-R83
-
-
Thomson, S.C.1
Rieg, T.2
Miracle, C.3
-
27
-
-
84892959743
-
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
-
PID: 24475922
-
Cherney DZI, Perkins BA, Soleymanlou N et al (2014) The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 13:28
-
(2014)
Cardiovasc Diabetol
, vol.13
, pp. 28
-
-
Cherney, D.Z.I.1
Perkins, B.A.2
Soleymanlou, N.3
-
28
-
-
84891856342
-
Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy
-
COI: 1:CAS:528:DC%2BC3sXhsl2ht7fM, PID: 24089538
-
Shimizu M, Furuichi K, Toyama T et al (2013) Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy. Diabetes Care 36:3655–3662
-
(2013)
Diabetes Care
, vol.36
, pp. 3655-3662
-
-
Shimizu, M.1
Furuichi, K.2
Toyama, T.3
-
29
-
-
84871369220
-
Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats
-
PID: 23227274
-
Osorio H, Coronel I, Arellano A et al (2012) Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats. Oxid Med Cell Longev 2012:542042
-
(2012)
Oxid Med Cell Longev
, vol.2012
, pp. 542042
-
-
Osorio, H.1
Coronel, I.2
Arellano, A.3
-
30
-
-
84873497173
-
Effects of SGLT2 inhibition in human kidney proximal tubular cells—renoprotection in diabetic nephropathy?
-
COI: 1:CAS:528:DC%2BC3sXivVOltrs%3D, PID: 23390498
-
Panchapakesan U, Pegg K, Gross S et al (2013) Effects of SGLT2 inhibition in human kidney proximal tubular cells—renoprotection in diabetic nephropathy? PLoS One 8, e54442
-
(2013)
PLoS One
, vol.8
-
-
Panchapakesan, U.1
Pegg, K.2
Gross, S.3
-
31
-
-
84903528312
-
Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice
-
PID: 24960177
-
Terami N, Ogawa D, Tachibana H et al (2014) Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One 9, e100777
-
(2014)
PLoS One
, vol.9
-
-
Terami, N.1
Ogawa, D.2
Tachibana, H.3
-
32
-
-
84920971105
-
Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus
-
COI: 1:CAS:528:DC%2BC2MXis12rtrY%3D, PID: 25377916
-
Lytvyn Y, Škrtić M, Yang GK, Yip PM, Perkins BA, Cherney DZ (2015) Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 308:F77–F83
-
(2015)
Am J Physiol Renal Physiol
, vol.308
, pp. F77-F83
-
-
Lytvyn, Y.1
Škrtić, M.2
Yang, G.K.3
Yip, P.M.4
Perkins, B.A.5
Cherney, D.Z.6
-
33
-
-
84928743782
-
Uric acid as a biomarker and a therapeutic target in diabetes
-
PID: 25600084
-
Lytvyn Y, Perkins BA, Cherney DZ (2015) Uric acid as a biomarker and a therapeutic target in diabetes. Can J Diabetes 39:239–246
-
(2015)
Can J Diabetes
, vol.39
, pp. 239-246
-
-
Lytvyn, Y.1
Perkins, B.A.2
Cherney, D.Z.3
-
34
-
-
44049101711
-
Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan
-
COI: 1:CAS:528:DC%2BD1cXmtlOgs7Y%3D, PID: 18272844
-
Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G (2008) Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 19:999–1007
-
(2008)
J Am Soc Nephrol
, vol.19
, pp. 999-1007
-
-
Vogt, L.1
Waanders, F.2
Boomsma, F.3
de Zeeuw, D.4
Navis, G.5
-
35
-
-
0025027402
-
Glomerular filtration rate in streptozotocin-induced diabetic rats. Role of exchangeable sodium, vasoactive hormones, and insulin therapy
-
COI: 1:CAS:528:DyaK3MXhsVSrtL4%3D, PID: 2170215
-
Allen TJ, Cooper ME, O’Brien RC, Bach LA, Jackson B, Jerums G (1990) Glomerular filtration rate in streptozotocin-induced diabetic rats. Role of exchangeable sodium, vasoactive hormones, and insulin therapy. Diabetes 39:1182–1190
-
(1990)
Diabetes
, vol.39
, pp. 1182-1190
-
-
Allen, T.J.1
Cooper, M.E.2
O’Brien, R.C.3
Bach, L.A.4
Jackson, B.5
Jerums, G.6
-
36
-
-
0023519539
-
Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration
-
COI: 1:CAS:528:DyaL2sXlslelsb8%3D, PID: 2957390
-
Ortola FV, Ballermann BJ, Anderson S, Mendez RE, Brenner BM (1987) Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration. J Clin Invest 80:670–674
-
(1987)
J Clin Invest
, vol.80
, pp. 670-674
-
-
Ortola, F.V.1
Ballermann, B.J.2
Anderson, S.3
Mendez, R.E.4
Brenner, B.M.5
-
37
-
-
84878060305
-
Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats
-
COI: 1:CAS:528:DC%2BC3sXptlOgsL4%3D, PID: 23492941
-
Kojima N, Williams JM, Takahashi T, Miyata N, Roman RJ (2013) Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther 345:464–472
-
(2013)
J Pharmacol Exp Ther
, vol.345
, pp. 464-472
-
-
Kojima, N.1
Williams, J.M.2
Takahashi, T.3
Miyata, N.4
Roman, R.J.5
-
38
-
-
84939565970
-
Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes
-
COI: 1:CAS:528:DC%2BC2MXotVWgsLg%3D, PID: 25960304
-
Cooper ME, Perkovic V, McGill JB et al (2015) Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis 66:441–449
-
(2015)
Am J Kidney Dis
, vol.66
, pp. 441-449
-
-
Cooper, M.E.1
Perkovic, V.2
McGill, J.B.3
|